PE20030986A1 - Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo) - Google Patents

Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo)

Info

Publication number
PE20030986A1
PE20030986A1 PE2003000132A PE2003000132A PE20030986A1 PE 20030986 A1 PE20030986 A1 PE 20030986A1 PE 2003000132 A PE2003000132 A PE 2003000132A PE 2003000132 A PE2003000132 A PE 2003000132A PE 20030986 A1 PE20030986 A1 PE 20030986A1
Authority
PE
Peru
Prior art keywords
amino
alkyl
biphenyl
methyl
fluor
Prior art date
Application number
PE2003000132A
Other languages
English (en)
Inventor
Neville J Anthony
Dong Mei Feng
Scott D Kuduk
Dai-Shi Su
Michael R Wood
Jenny Miu-Chun Wai
Mark G Bock
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of PE20030986A1 publication Critical patent/PE20030986A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE REFIERE A DERIVADOS DE N-BIFENIL-AMINOCICLOALCANCARBOXAMIDA (CON SUSTITUCION CON METILO) DE FORMULA I DONDE R1 Y R2 SON H, ALQUILO C1-C4; R3a ES H, ALQUILO C1-C4; R3b ES ALQUILO C1-C4 CON 1-5 ATOMOS DE HALOGENO; R4a Y R4b SON H, HALOGENO Y ALQUILO C1-C4; R5 ES ALQUILO C1-C6, CICLOALQUILO C3-C8, ALQUINILO C3-C6, ALQUENILO C2-C6, ENTRE OTROS; R6b Y R6c SON H, R6a CON LA CONDICION DE QUE NO MAS DE UNO DE R6a, R6b Y R6c SEA UN HETEROCICLO; R7a Y R7b SON H, HALOGENO, CIANO, NITRO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS METIL -3-FLUOR-4´{(1R)-1-[({1-[(3,3,3-TRIFLUORPROPANOIL)AMINO]CICLOPROPIL}CARBONIL)AMINO]ETIL}-1,1'-BIFENIL-2-CARBOXILATO, -3-FLUOR-N-METOXI-4´{(1R)-1-[({1-[(3,3,3-TRIFLUORPROPANOIL)AMINO]CICLOPROPIL}CARBONIL)AMINO]ETIL}-1,1'-BIFENIL-2-CARBOXAMIDA, METIL 3-FLUOR-4´{1-METIL-1-[({1-[(TRIFLUOROACETIL)AMINO]CICLOPROPIL}CARBONIL)AMINO]ETIL}-1,1'-BIFENIL-2-CARBOXILATO, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DEL DOLOR, OSTEOARTRITIS, ENFERMEDAD OBSTRUCTIVA CRONICA
PE2003000132A 2002-02-08 2003-02-04 Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo) PE20030986A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35506202P 2002-02-08 2002-02-08
US41017202P 2002-09-12 2002-09-12

Publications (1)

Publication Number Publication Date
PE20030986A1 true PE20030986A1 (es) 2003-11-19

Family

ID=27737481

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000132A PE20030986A1 (es) 2002-02-08 2003-02-04 Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo)

Country Status (27)

Country Link
US (2) US6919343B2 (es)
EP (1) EP1501787B1 (es)
JP (1) JP4098249B2 (es)
KR (1) KR20040083440A (es)
CN (1) CN1328247C (es)
AR (1) AR038377A1 (es)
AT (1) ATE309202T1 (es)
AU (1) AU2003216169B2 (es)
BR (1) BR0307508A (es)
CA (1) CA2474373C (es)
DE (1) DE60302240T2 (es)
DK (1) DK1501787T3 (es)
EA (1) EA007297B1 (es)
EC (1) ECSP045217A (es)
ES (1) ES2250899T3 (es)
HR (1) HRP20040677A2 (es)
IS (1) IS7372A (es)
JO (1) JO2356B1 (es)
MA (1) MA27108A1 (es)
MX (1) MXPA04007660A (es)
NO (1) NO20043739L (es)
NZ (1) NZ534062A (es)
PE (1) PE20030986A1 (es)
PL (1) PL371664A1 (es)
RS (1) RS65404A (es)
TW (1) TWI259079B (es)
WO (1) WO2003066577A1 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1466904A4 (en) * 2001-12-28 2005-12-14 Takeda Pharmaceutical BIARYL CONNECTION AND ITS USE
WO2003065789A2 (en) * 2002-02-08 2003-08-14 Merck & Co., Inc. N-biphenylmethyl aminocycloalkanecarboxamide derivatives
CN1678320A (zh) * 2002-08-29 2005-10-05 麦克公司 N－联芳基甲基氨基环烷酰胺衍生物
AU2003299757A1 (en) * 2002-12-19 2004-07-14 Elan Pharmaceuticals Inc. Substituted n-phenyl sulfonamide bradykinin antagonists
AU2004265300A1 (en) * 2003-08-07 2005-02-24 Merck & Co., Inc. Sulfonyl substituted N-(biarylmethyl) aminocyclopropanecarboxamides
AU2004309357B2 (en) * 2003-12-22 2010-10-07 Merck Sharp & Dohme Corp. Alpha-hydroxy amides as bradykinin antagonists or inverse agonists
CA2557858A1 (en) * 2004-03-02 2005-09-15 Merck & Co., Inc. Amino cyclopropane carboxamide derivatives as bradykinin antagonists
US20050245543A1 (en) * 2004-04-30 2005-11-03 Pfizer Inc Histamine-3 receptor antagonists
EP1773354A4 (en) * 2004-08-02 2010-05-05 Bebaas Inc COMPOSITIONS OF VITAMIN B12
DE102004060542A1 (de) * 2004-12-16 2006-07-06 Sanofi-Aventis Deutschland Gmbh Hydroxybiphenyl-Carbonsäuren und Derivate, Verfahren zu deren Herstellung und deren Verwendung
PL1830869T3 (pl) 2004-12-24 2013-11-29 Novartis Ag Sposób leczenia lub profilaktyki
US20070178141A1 (en) * 2005-09-07 2007-08-02 Bebaas, Inc. Vitamin B12 compositions
US20130131007A1 (en) 2005-09-07 2013-05-23 Bebaas, Inc. Vitamin b12 compositions
CN101443001B (zh) 2006-03-20 2013-11-13 西芬克斯医药有限公司 治疗或预防炎性痛的方法
US8945505B2 (en) 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
EP2155643B1 (en) 2007-06-08 2016-08-10 MannKind Corporation Ire-1a inhibitors
EP2188254B1 (de) * 2007-08-29 2012-03-21 Boehringer Ingelheim International GmbH Neue bradykinin b1-antagonisten
WO2009132453A1 (en) * 2008-04-28 2009-11-05 Neuromed Pharmaceuticals Ltd. Cyclylamine derivatives as calcium channel blockers
WO2010097374A1 (de) * 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Verbindungen als bradykinin-b1-antagonisten
RS52801B (en) * 2009-02-26 2013-10-31 Boehringer Ingelheim International Gmbh UNITS AS BRADIKININ-B1 ANTAGONISTS
WO2010097373A1 (de) * 2009-02-26 2010-09-02 Boehringer Ingelheim International Gmbh Verbindungen als bradykinin b1 antagonisten
US10457810B2 (en) 2009-08-24 2019-10-29 Board Of Trustees Of Michigan State University Densified biomass products containing pretreated biomass fibers
KR101843341B1 (ko) * 2010-02-23 2018-03-30 베링거 인겔하임 인터내셔날 게엠베하 브라디키닌 ｂ１ 길항제로서의 화합물
CN102939388B (zh) 2010-04-19 2016-08-03 密歇根州立大学董事会 可消化木质纤维素生物质和提取物及其制备方法
US8937073B2 (en) 2010-08-20 2015-01-20 Boehringer Ingelheim International Gmbh Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists
HUP1000598A2 (en) * 2010-11-05 2012-09-28 Richter Gedeon Nyrt Indole derivatives
US8912221B2 (en) * 2010-12-27 2014-12-16 Hoffmann-La Roche Inc. Biaryl amide derivatives
US8592426B2 (en) * 2011-01-24 2013-11-26 Hoffmann—La Roche Inc. Aryl-benzocycloalkyl amide derivatives
MX2020004557A (es) 2017-11-02 2020-10-05 Calico Life Sciences Llc Moduladores de la vía de estrés integrada.
TWI771621B (zh) 2018-10-11 2022-07-21 美商嘉來克生命科學有限責任公司 整合應激路徑之前藥調節劑

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270317A (en) 1990-03-20 1993-12-14 Elf Sanofi N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present
IL99372A0 (en) 1990-09-10 1992-08-18 Ciba Geigy Ag Azacyclic compounds
US5208236A (en) 1992-09-23 1993-05-04 Schering Corporation N-(acylaminomethyl)glutaryl amino acids and use
DE69424846T2 (de) 1993-11-16 2000-11-16 Novartis Ag Zyklische Aminosäure-Derivate mit ACE und NEP inhibierender Aktivität
AU7211696A (en) 1995-09-27 1997-04-17 Ciba-Geigy Ag Treatment of chronic progressive renal failure
US6433185B1 (en) 1996-01-11 2002-08-13 Sanofi-Synthelabo N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them
FR2743562B1 (fr) 1996-01-11 1998-04-03 Sanofi Sa Derives de n-(arylsulfonyl) aminoacides, leur preparation, les compositions pharmaceutiques en contenant
IL138688A0 (en) 1998-04-23 2001-10-31 Novartis Ag Certain heteroaryl substituted thiol inhibitors of endothelin-converting enzyme
RU2000129510A (ru) 1998-04-23 2002-11-10 Новартис АГ (CH) Определенные тиольные ингибиторы эндотелинпревращающих ферментов
US20020052370A1 (en) 2000-07-06 2002-05-02 Barber Christopher Gordon Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase
DE10036121A1 (de) 2000-07-25 2002-02-07 Merck Patent Gmbh N-Substituierte-1-amino-1,1-dialkyl-carbonsäurederivate
WO2003065789A2 (en) 2002-02-08 2003-08-14 Merck & Co., Inc. N-biphenylmethyl aminocycloalkanecarboxamide derivatives

Also Published As

Publication number Publication date
HRP20040677A2 (en) 2005-06-30
EP1501787A1 (en) 2005-02-02
IS7372A (is) 2004-07-26
CN1630633A (zh) 2005-06-22
EA200401054A1 (ru) 2005-02-24
KR20040083440A (ko) 2004-10-01
MA27108A1 (fr) 2004-12-20
AU2003216169A1 (en) 2003-09-02
NO20043739L (no) 2004-10-29
JP2005517006A (ja) 2005-06-09
WO2003066577A1 (en) 2003-08-14
JP4098249B2 (ja) 2008-06-11
PL371664A1 (en) 2005-06-27
ES2250899T3 (es) 2006-04-16
BR0307508A (pt) 2004-12-07
TW200302718A (en) 2003-08-16
DE60302240D1 (de) 2005-12-15
CA2474373C (en) 2009-05-26
CA2474373A1 (en) 2003-08-14
JO2356B1 (en) 2006-12-12
AR038377A1 (es) 2005-01-12
EP1501787B1 (en) 2005-11-09
US20030220375A1 (en) 2003-11-27
TWI259079B (en) 2006-08-01
AU2003216169B2 (en) 2008-12-04
EA007297B1 (ru) 2006-08-25
US20050084463A1 (en) 2005-04-21
ATE309202T1 (de) 2005-11-15
ECSP045217A (es) 2004-09-28
NZ534062A (en) 2006-06-30
MXPA04007660A (es) 2004-11-10
US6919343B2 (en) 2005-07-19
DK1501787T3 (da) 2006-03-20
RS65404A (en) 2007-02-05
CN1328247C (zh) 2007-07-25
DE60302240T2 (de) 2006-07-13

Similar Documents

Publication Publication Date Title
PE20030986A1 (es) Derivados de n-bifenil-aminocicloalcancarboxamida (con sustitucion con metilo)
NO20034986L (no) Furan og tiofenderivater som aktiverer human peroksisom proliferator aktiverte reseptorer
PE20020722A1 (es) Derivados de glucopiranosiloxipirazol como inhibidor del sglt2 humano
BRPI0418245A (pt) nitróxi-derivados de prostaglandina
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
HK1085667A1 (en) Non-nucleoside reverse transcriptase inhibitors
CL2009001278A1 (es) Compuestos biciclicos, derivados de 1-(4-pipridinil)-1,3-dihidro-2h-indol-2-ona sustituidos, analogos de nociceptina; composicion farmaceutica; y su uso en el tratamiento del dolor (div. sol. 2103-03)
MXPA05013733A (es) 2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
CO4960641A1 (es) Derivados de piperidina 1,4-disustituida conteniendo fluor
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
PE20050346A1 (es) Glucopiranosiloxi-pirazoles como inhibidores del co-transportador de glucosa dependiente de sodio (sglt2)
LU92155I2 (fr) Crizotinib, éventuellement sous la forme d'un sel,hydrate ou solvate pharmeceutiquement acceptable
MXPA06001273A (es) Compuestos novedosos.
NL980008I1 (nl) Gebruik van sertindool voor de behandeling van schizofrenie.
PE20060999A1 (es) Composiciones farmaceuticas que contienen un diuretico y un bloqueador del receptor de angiotensina ii
PE20011269A1 (es) DERIVADOS DE 9-(5-HETEROARILTETRAHIDROFURANIL)-PURINA COMO AGONISTAS SELECTIVOS DEL RECEPTOR A2a DE LA ADENOSINA
EA201100129A1 (ru) Композиции и способы применения модулятора рецептора 5ht-2c
SG164283A1 (en) New benzimidazole derivatives
AR054083A1 (es) Compuestos imidazol y su utilizacion paar preparar medicamentos
MXPA04001209A (es) Farmaco con efecto neuroprotector.
PE20060533A1 (es) Derivados de dicetopiperazina como antagonistas del receptor de oxitocina
CL2002001701A1 (es) Uso de al menos un compuesto seleccionado entre melatonina, agentes melatoninergicos, agonistas y antagonistas de melatonina, en una cantidad de 0,0025-50 mg, para preparar un medicamento util para el tratamiento y mejora de la calidad repadora del sueno.
PE20000701A1 (es) Combinacion de fentolamina y apomorfina para el tratamiento de la funcion y disfuncion sexual humana
PE20040903A1 (es) Derivados de nucleosido antivirales
PE20020557A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 para tratar la disfuncion sexual

Legal Events

Date Code Title Description
FC Refusal